Drug Approval | October 20, 2023
USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Increased capability to produce medicines for challenging diseases including cancer
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
